Afuresertib vs NTQ1062

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: AKT (inhibitor) · full HR+/HER2- Metastatic Breast Cancer pipeline

Afuresertib

Developed by Laekna Limited under a licence from Novartis

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule (AKT inhibitor)
Partial signal

NCT04851613 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 256 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Reported efficacy

Phase I: Overall Response Rate (ORR) based on RECIST 1.1 (Phase I: Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks × 40 weeks then every 3 months through study completion, an average of 1 year (each cycle is 28 days)); Phase III: Progression Free Survival (PFS) based on RECIST 1.1, as assessed by investigators (Phase III:Change from Baseline beginning at Cycle 3 Day 1 and then every 8 weeks for the first 12 months, then every 3 months through study completion): Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). (met)

Result source: NCT04851613

NTQ1062

Developed by Sino Biopharmaceutical

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07393321 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAfuresertibNTQ1062
PFS, median—Trial running · NCT04851613—Trial running · NCT07393321
OS, median—Trial running · NCT04851613—Trial running · NCT07393321
ORR—Trial running · NCT04851613—Trial running · NCT07393321
Clinical benefit rate—Trial running · NCT04851613—Trial running · NCT07393321

PFS, median

Afuresertib
—Trial running · NCT04851613
NTQ1062
—Trial running · NCT07393321

OS, median

Afuresertib
—Trial running · NCT04851613
NTQ1062
—Trial running · NCT07393321

ORR

Afuresertib
—Trial running · NCT04851613
NTQ1062
—Trial running · NCT07393321

Clinical benefit rate

Afuresertib
—Trial running · NCT04851613
NTQ1062
—Trial running · NCT07393321
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NTQ1062: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Afuresertib
Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15). NCT04851613 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afuresertib's landscape · NTQ1062's landscape